Genomic & Biopharma NewsTurning Point Therapeutics eyes $100M IPO to propel treatment for drug-resistant tumors
Turning Point Therapeutics has filed to raise up to $100 million in its Nasdaq debut. The proceeds will push its lead asset, repotrectinib, into phase 2 studies and to advance a pair of earlier-stage programs in advanced solid tumors.
|Fierce Biotech, 2019-03-22 14:49:09|
Alcon will officially leave Novartis on April 9 after an 8-year run. What's next?
Exactly eight years into its full ownership of Alcon, Novartis will officially say goodbye to the eye care business on April 9. The spinoff follows Novartis' recent sale of its stake in a GlaxoSmithKline consumer joint venture and some Sandoz generics.
|Fierce Pharma, 2019-03-22 14:26:49|
Allele Shows Pyrethroid Resistance's Spread in African Mosquitos
Researchers can now track the expansion of a resistance mechanism that allows the malaria vector Anopholes funestus to detoxify a key insecticide used on bed nets.
|The Scientist, 2019-03-22 14:24:21|
Trump Signs Executive Order Tying Grant Money to Free Speech
It's unclear how the order, which charges academic institutions to follow existing rules regarding the First Amendment, will be implemented and enforced.
|The Scientist, 2019-03-22 14:20:55|
Impulse Dynamics wins FDA approval for breakthrough heart implant
The FDA has approved another one of its breakthrough devices: an implant from Impulse Dynamics designed for patients with chronic heart failure who aren’t able to use a pacemaker or standard cardiac resynchronization therapy.
|Fierce Biotech, 2019-03-22 13:50:24|
Electronic Sun Sentinel: Gene analysis lab moves to Deerfield Beach
|ORB Company News, 2016-12-02 21:24:27|
Democrats push back at North American trade deal over biologic drug exclusivity
Amid a national conversation over drug prices, Democrats are raising concern with the trade deal negotiated between the U.S., Canada and Mexico.
|Fierce Pharma, 2019-03-22 13:38:45|
Long-term data shows promise in breast cancer biosimilar
The a three-year follow-up study comparing Ontruzant to Herceptin has found the biosimilar to be just as successful.
|PharmaTimes, 2019-03-22 13:18:00|
Sun Sentinel: Ocean Ridge Biosciences expands to 5,400-square foot facility
Ocean Ridge Biosciences is a survivor in South Florida's fledgling biotech industry. In the past decade, Ocean Ridge has worked with more than 200 academic labs and companies, providing gene-based lab analysis of blood and tissue samples for the development of new drugs and diagnostic tests.
|ORB Company News, 2016-12-28 18:58:47|
Multi-drug approach found to attack resistance in bowel cancer
A new study has shown that triple drug combinations could prevent resistance in many cancer types.
|PharmaTimes, 2019-03-22 13:16:57|
£23 million funding for cutting edge health projects
£23 million of government funding has been awarded to cutting edge health projects.
|PharmaTimes, 2019-03-22 13:16:19|